scPharmaceuticals Inc.
SCPH
$2.57
$0.020.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 167.28% | 303.87% | 549.77% | 754.68% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 167.28% | 303.87% | 549.77% | 754.68% | -- |
| Cost of Revenue | 198.11% | 349.90% | 623.36% | 724.96% | -- |
| Gross Profit | 155.27% | 286.68% | 524.03% | 767.01% | -- |
| SG&A Expenses | 45.49% | 63.68% | 79.26% | 109.31% | 158.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.56% | 64.46% | 74.09% | 81.80% | 90.80% |
| Operating Income | -16.93% | -28.30% | -34.79% | -47.50% | -53.21% |
| Income Before Tax | -55.35% | -59.45% | -35.44% | -43.14% | -48.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.35% | -59.45% | -35.44% | -43.14% | -48.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.35% | -59.45% | -35.44% | -43.14% | -48.79% |
| EBIT | -16.93% | -28.30% | -34.79% | -47.50% | -53.21% |
| EBITDA | -16.95% | -28.33% | -34.83% | -47.57% | -53.30% |
| EPS Basic | -34.13% | -40.33% | -17.36% | -12.89% | -9.08% |
| Normalized Basic EPS | -30.92% | -46.40% | -21.49% | -17.04% | -13.26% |
| EPS Diluted | -34.13% | -40.33% | -17.36% | -12.89% | -9.08% |
| Normalized Diluted EPS | -30.92% | -46.40% | -21.49% | -17.04% | -13.26% |
| Average Basic Shares Outstanding | 15.53% | 11.45% | 15.05% | 25.32% | 35.84% |
| Average Diluted Shares Outstanding | 15.53% | 11.45% | 15.05% | 25.32% | 35.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |